Dr. Matthew Sorrentino is a non-invasive preventive cardiologist with expertise and research interests in treating hyperlipidemia (high cholesterol), hypertension and coronary artery disease. He is a general cardiologist, and he treats patients with all types of heart disease and risk factors for heart disease.
A popular speaker, Dr. Sorrentino has been invited to give lectures and run education programs at more than 500 local, national and international meetings and events. He has written numerous publications on preventive cardiology, including a recent book, “Hyperlipidemia in Primary Care”.
In 1999, Dr. Sorrentino was designated a specialist in hypertension by the American Society of Hypertension. In addition, he was honored by Chicago magazine as one of the top cardiologists in the Chicago area in 2000, 2008, 2010 and 2011. He was named as one of the Best Doctors in America in 2007. In 2011, he was appointed the Associate Director of the Bucksbaum Institute for Clinical Excellence.
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial.
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial. Lancet Neurol. 2025 Apr; 24(4):295-304.
PMID: 40120614
Preface.
Preface. Acad Med. 2023 06 01; 98(6S):S1-S2.
PMID: 36812045
The Bucksbaum Institute for Clinical Excellence and the Doctor-Patient Relationship: Origins, Programs, and Future Directions.
The Bucksbaum Institute for Clinical Excellence and the Doctor-Patient Relationship: Origins, Programs, and Future Directions. Acad Med. 2023 06 01; 98(6S):S3-S5.
PMID: 36811976
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
PMID: 30476251
The Evolution from Hypertension to Heart Failure.
The Evolution from Hypertension to Heart Failure. Heart Fail Clin. 2019 Oct; 15(4):447-453.
PMID: 31472880
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
PMID: 30713337
Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.
Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38.
PMID: 30531377
Perspective on the New Blood-Pressure Guidelines.
Perspective on the New Blood-Pressure Guidelines. Eur Heart J. 2018 Sep 01; 39(33):3008-3009.
PMID: 30990868
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. J Cardiovasc Pharmacol Ther. 2019 01; 24(1):54-61.
PMID: 29940784
Redefining Hypertension - Assessing the New Blood-Pressure Guidelines.
Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018 02 08; 378(6):497-499.
PMID: 29341841